The Asthma Landscape in America
Asthma touches every corner of the country, though not equally. Recent CDC surveillance data shows prevalence has been climbing among adults in the United States, while children have seen a modest decline over the past decade. The burden falls heaviest on non-Hispanic Black communities, where roughly 12.5% of children and 10.6% of adults live with the condition. Among non-Hispanic White populations, those figures sit at 5.7% and 8.2% respectively.
What makes asthma particularly disorienting is its unpredictability. A person might feel fine for weeks, then suddenly face an attack triggered by pollen, cold air, or a respiratory virus. For the estimated 5% to 10% of patients with severe asthma, standard treatments—inhaled corticosteroids, long-acting bronchodilators, and oral steroids—simply do not provide enough control. This is the space where clinical research becomes not just an option, but a serious consideration.
Across the United States, hundreds of asthma clinical trials are actively recruiting participants. They span academic medical centers, community hospitals, and private research facilities, investigating everything from novel biologic therapies to behavioral interventions aimed at improving medication adherence. The National Institutes of Health lists studies in every region, though major metropolitan areas like Boston, Houston, New York, and Los Angeles tend to have the highest concentration of active sites.
Types of Trials and What They Investigate
Not all asthma studies are alike, and understanding the terrain helps potential participants make informed choices.
Phase I studies typically involve small groups and focus on safety and dosage. These are less common for patients to join directly. Phase II trials expand the scope, looking at how well a treatment works while continuing to monitor side effects. Phase III studies compare the new approach against existing standard treatments, often across hundreds or thousands of participants at multiple sites. Phase IV research happens after a treatment reaches the market, tracking long-term safety and real-world outcomes.
The current wave of asthma research leans heavily toward biologic therapies. These medications target specific immune system pathways rather than broadly suppressing inflammation. Drugs like dupilumab, mepolizumab, benralizumab, and tezepelumab have reshaped care for people with eosinophilic or allergic asthma. A pooled analysis of clinical trials published in 2025 found that biologics reduced asthma exacerbations requiring hospitalization or emergency department visits by an estimated 56%.
Beyond biologics, researchers are investigating adherence tools. A randomized trial conducted at a large mid-Atlantic pediatric health system tested whether daily text reminders combined with modest financial incentives could improve inhaler use among children at high risk for exacerbations. Studies like these reflect a growing recognition that medicine alone is not enough—behavior and environment matter too.
Other active areas include environmental interventions for World Trade Center responders with asthma, bacterial extract supplements for preventing wheezing in young children, and imaging studies that examine how lung airways and blood vessels respond to biologic therapy. The DOMINICA trial, for example, is currently evaluating benralizumab in pediatric patients aged 6 to under 18 with severe eosinophilic asthma, a group that has historically had fewer treatment options than adults.
Here is a comparison of common trial categories:
| Trial Type | Typical Duration | Participant Profile | Key Benefit | Considerations |
|---|
| Biologic therapy trials | 24–52 weeks | Moderate to severe eosinophilic or allergic asthma | Access to emerging treatments | Frequent clinic visits; possible placebo arm |
| Behavioral/adherence studies | 3–12 months | Children and adults with uncontrolled asthma | Non-invasive; provides practical tools | May require daily tracking |
| Prevention trials | 1–4 years | Infants and young children at risk | Long-term disease prevention focus | Extended time commitment |
| Observational studies | Variable | Any asthma diagnosis | No intervention required; contributes to science | No direct treatment benefit |
What Participation Actually Looks Like
Maria, a 42-year-old teacher in Texas, spent years cycling through inhalers and oral steroids. Her asthma attacks kept her out of the classroom for days at a time. After her pulmonologist mentioned a clinical trial for a biologic targeting eosinophilic inflammation, she enrolled at a research site in Houston. The screening process involved blood work, lung function tests, and a review of her medical history. Once accepted, she received injections every four weeks at the clinic, with regular check-ins to monitor her breathing and any side effects.
Her experience reflects a common pattern. Screening visits tend to be thorough—researchers need to confirm that a participant meets the study's inclusion criteria and has no disqualifying conditions. Lung function tests like spirometry are standard. Blood draws measure eosinophil counts or other biomarkers depending on the study's focus. Some trials require keeping a symptom diary or using a peak flow meter at home.
Compensation varies by study length and intensity. Some research centers offer modest payments for each completed visit. A university-based asthma institute might provide a small reimbursement for time and parking. Longer pediatric trials sometimes offer gift cards totaling several hundred to a few thousand dollars over the full study period. The key detail is that the investigational treatment itself, along with study-related medical exams and monitoring, is provided at no cost to participants. This can be meaningful for families facing high medication expenses.
Time commitment is the factor that surprises many newcomers. While some observational studies require only occasional visits, a Phase III biologic trial might involve monthly clinic trips for a year or more. Participants should ask about the visit schedule during the informed consent process and consider whether they can realistically accommodate it. Severe asthma clinical trials often demand the most from participants, but they also tend to offer the most intensive monitoring and support.
Finding Trials and Asking the Right Questions
ClinicalTrials.gov, maintained by the National Library of Medicine, remains the most comprehensive resource for locating asthma clinical trials near me. The search tool allows filtering by condition, location, and recruitment status. Entering "asthma" as the condition and a zip code with a 50-mile radius typically surfaces dozens of active studies. Academic medical centers—such as those affiliated with the University of Pittsburgh, Boston Children's Hospital, or Mount Sinai in New York—often run dedicated asthma research programs and maintain their own enrollment pages.
Referrals from a treating physician carry weight. Pulmonologists and allergists frequently know about trials recruiting in their region and can assess whether a patient's clinical profile aligns with what researchers are seeking. This is especially relevant for biologic asthma trials, which often require specific biomarker thresholds like elevated eosinophil counts.
Questions worth asking before enrolling include: What is the study phase, and what is known about the treatment so far? How many visits will be required, and where will they take place? Is there a possibility of receiving a placebo, and if so, for how long? What happens after the trial ends—is there an extension study or a transition plan? Will the study team communicate results to participants?
Federal regulations and institutional review boards provide layers of protection for research volunteers. The informed consent document outlines risks, benefits, and the right to withdraw at any time without penalty. Reading it carefully and discussing concerns with the study coordinator is a reasonable step before committing.
Pediatric asthma clinical trials deserve special consideration. Watching a child undergo blood draws or spend hours at a research clinic can be difficult. But for families whose children have struggled with severe asthma despite trying multiple treatments, the opportunity to access emerging therapies can outweigh the burden. Parents should ask about child life specialists, comfort measures during procedures, and how the research team handles young participants' anxiety.
Regional Resources and Practical Considerations
Seasonal timing can affect enrollment. Many asthma trials see spikes in recruitment during spring and fall, when allergens and respiratory viruses trigger more exacerbations. Planning ahead and getting on a research center's contact list can help prospective participants learn about asthma research studies enrolling now as they open.
Insurance considerations are worth clarifying. Routine care that would be needed regardless of the trial—such as standard asthma medications or primary care visits—typically remains the patient's responsibility. Study-related procedures and the investigational drug are covered by the trial sponsor. The research team should explain this distinction clearly during the screening process. For those concerned about costs, some asthma clinical trial compensation programs include travel reimbursements that help offset the logistical burden of participation.
The American Lung Association and the Asthma and Allergy Foundation of America both maintain directories and educational materials about clinical research participation. Local chapters sometimes host informational events where patients can meet researchers and learn about ongoing studies in a low-pressure environment. These gatherings can be a useful starting point for anyone curious about asthma treatment trials but hesitant to commit to a screening visit right away.
Clinical research is not a replacement for standard medical care. It is a voluntary path that some people choose when existing treatments fall short or when they want to contribute to knowledge that might help others. The decision to enroll deserves the same thoughtful consideration as any other health choice—weighed against personal circumstances, discussed with trusted providers, and made with a clear understanding of what lies ahead. If you have been wondering whether an asthma clinical trial might be right for you, a conversation with your physician or a call to a local research center is a practical place to start.
研究の知恵